Wednesday, June 26, 2024
ProBio Inc., a prominent contract development and manufacturing organization (CDMO) based in New Jersey, has inaugurated a state-of-the-art facility in Hopewell, New Jersey, aimed at expanding its capabilities in manufacturing plasmid DNA and viral vectors. This new facility, covering approximately 128,000 square feet, includes office, laboratory, and manufacturing spaces equipped with cutting-edge technology for process development and current good manufacturing practice (cGMP) production.
The facility is strategically positioned to support ProBio's operations in North America, focusing on producing crucial biologics such as adeno-associated virus, lentivirus, and retrovirus for cell and gene therapies. It will facilitate tech transfer, method development, analytical testing, and manufacturing of both clinical and commercial-grade plasmid DNA and viral vectors, all under rigorous quality control and assurance protocols.
Earlier this year, ProBio received the 2024 CDMO Leadership Award for its excellence in Compatibility, Quality, and Reliability, underscoring its commitment to advancing transformative therapies in biotechnology and pharmaceuticals.
"We are thrilled to enhance our capabilities in biologic drug manufacturing, particularly in support of cell and gene therapies," said Li Chen, Chief Executive Officer of ProBio Inc. "Our team and advanced facility in Hopewell, N.J., are dedicated to accelerating the delivery of these innovative therapies to patients."
ProBio Inc., highlighted the facility's role in translating innovative therapies into reality, reinforcing ProBio's leadership in the biotech industry. Renovations of the cGMP suites will further enhance the company's capacity to support phase-appropriate programs and drive future advancements in biologic manufacturing.
Source: prnewswire.com
